Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.


Home > Dermatology > EADV 2023 > Hidradenitis Suppurativa: End of the Diagnostic and Therapeutic Draught > Nanobodies: A novel way to treat HS

Nanobodies: A novel way to treat HS

Presented by
Prof. Brian Kirby, St. Vincent´s University Hospital, Ireland
Conference
EADV 2023
Trial
Phase 2, MIRA
Doi
https://doi.org/10.55788/8861a327
    In the phase 2 MIRA trial, the nanobody sonelokimab led to a remarkable clinical response in patients with hidradenitis suppurativa (HS). Due to its small size, the agent can easily penetrate inflamed tissue, which might explain its distinct efficacy.

    A large and unmet need exists for a more effective therapy in the management of HS. An interesting novel agent under investigation is the nanobody sonelokimab, a humanised antibody targeting IL-17A and IL-17F. Increasing evidence highlights IL-17A and IL-17F-mediated inflammation in HS pathogenesis. “Some patients go on to develop tunnels and draining fistulas. And we know that IL-17A and IL-17F are even higher in those with tunnels compared with patients that don’t develop tunnels,” Prof. Brian Kirby (St. Vincent´s University Hospital, Ireland) explained [1]. In addition, there is an albumin-binding domain. Due to its small molecular size and its ability to bind to albumin, sonelokimab is able to penetrate inflamed tissue which is otherwise difficult-to-treat; thus, directly targeting the site of inflammation.

    Prof. Kirby presented the 12-week results of the double-blind, placebo-controlled, phase 2 MIRA trial (NCT05322473). This trial included adult patients with HS, Hurley stage II/III, a total abscess and/or inflammatory nodule count of ≥5, and the presence of HS lesions in ≥2 anatomical regions. They received either 120 mg or 240 mg sonelokimab, placebo, or adalimumab as an active comparator (to validate clinical findings but not powered for any statistical comparison). The primary study endpoint was the proportion of participants achieving a ≥75% reduction in total nodule counts from baseline with no new abscess or tunnel draining count (i.e. HiSCR 75).

    All in all, 234 participants could be included and >95% completed week 12. Significantly more participants treated with sonelokimab achieved the primary endpoint at week 12 compared with placebo (43.3% treated with 120 mg and 34.8% treated with 240 mg vs 14.7% in the placebo group; P<0.001 for the first and P<0.01 for the second comparison; see Figure).

    Figure: Sonelokimab met the primary endpoint of HiSCR75 at week 12 [1]



    “Sonelokimab works quickly. We see significant differences versus placebo as early as week 8,” Prof. Kirby said. Moreover, sonelokimab improved quality of life, as measured by the Dermatology Life Quality Index (DLQI; i.e. improvement of ≥4 points, which is considered clinically relevant) and led to less skin pain.

    The nanobody was well tolerated in accordance with its known safety profile. Candida infections occurred more frequently in the sonelokimab groups (e.g. 6% cases of oral candidiasis in the low-dose group and 12.1% in the high-dose group compared with no cases in the placebo group) but were generally mild-to-moderate and did not lead to treatment withdrawal.


      1. Kirby B, et al. Efficacy and safety of the IL-17A- and IL-17F-inhibiting Nanobody® Sonelokimab in patients with active, moderate-to-severe hidradenitis suppurativa: Results from the global, randomized, double-blind, placebo-controlled phase 2 MIRA trial. D1T01.1H, EADV Congress 2023, 11–14 October, Berlin, Germany.

     

    Copyright ©2023 Medicom Medical Publishers



    Posted on